Transarterial chemoembolization of advanced liver XXXX of @entity5 --a retrospective single-center analysis.

@entity1 @entity788 @entity5 @entity4303 @entity3 @entity2390
BACKGROUND: In @entity5 , @entity3 are a negative prognostic factor for survival and quality of life. Transcatheter arterial chemoembolization (TACE) is thought to be an effective symptomatic and antiproliferative treatment in @entity1 with otherwise progressive disease. METHODS: 62 chemoembolization procedures in 26 @entity1 with progressive @entity5 were reviewed. The underlying disease was @entity4303 in 10, @entity5 in 2, @entity788 in 7, @entity5 in 2 @entity1 , @entity5 of the stomach in 1 and of unknown origin in 4 @entity1 . Tumor burden of the liver was <25% in 3, 25-50% in 11, 50-75% in 6 and >75% in 6 @entity1 . RESULTS: TACE was technically successful in 57 cases. Four @entity1 developed minor and 5 major complications. The 30-day mortality rate was 7.7%. According to WHO criteria, 14 @entity1 had no change in @entity5 burden, 2 had regression and 5 progress after chemoembolization. @entity1 with a @entity5 burden >75% of the liver did not benefit from TACE due to the development of major complications, whereas @entity1 with low (<50%) @entity5 burden and high (>50%) lipiodol uptake showed a trend towards longer survival. Five-year survival time after diagnosis was 48%. @entity1 treated with @entity2390 and/or alpha-interferon had no benefit from chemoembolization with regard to their @entity4303 . CONCLUSIONS: In this retrospective study, @entity1 with low (<50%) @entity5 burden and high (>50%) lipiodol uptake responded better to TACE than end-stage @entity1 .
